Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMBQ5OL)

Drug Name

VIP-152 Drug Info

Synonyms

Enitociclib; 1255AT22ZJ; UNII-1255AT22ZJ; VIP152; CHEMBL4762845; VIP-152; BAY-1251152; 1610408-97-3; 2-Pyridinamine, 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-(4-(((S(S))-S-methylsulfonimidoyl)methyl)-2-pyridinyl)-; 2-Pyridinamine, 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-[4-[[[S(S)]-S-methylsulfonimidoyl]methyl]-2-pyridinyl]-; ENITOCICLIB [INN]; ENITOCICLIB [USAN]; GTPL11686; GLXC-26844; BDBM50556034; BAY 1251152; csc(S)-[(2-{[5-fluoro-4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl]amino}pyridin-4-yl)methyl](imino)(methyl)-l6-sulfanone

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 1	[1]
Non-hodgkin lymphoma	2B33.5	Phase 1	[1]

Cross-matching ID

PubChem CID: 139593425
TTD Drug ID: DMBQ5OL

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cyclin-dependent kinase 9 (CDK9)	TT1LVF2	CDK9_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Cyclin-dependent kinase 9 (CDK9)	DTT	CDK9	5.597	5.711	5.221	5.776

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Chronic lymphocytic leukaemia

ICD Disease Classification

2A82.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Cyclin-dependent kinase 9 (CDK9)	DTT	CDK9	4.38E-01	-0.04	-0.1

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT04978779) An Open-label, Multicenter Phase 1/1b Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP152 Monotherapy or Combination Therapy in Subjects With High-risk Chronic Lymphocytic Leukemia or Richter Syndrome. U.S.National Institutes of Health.
2	VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia. Leukemia. 2023 Feb;37(2):326-338.